Lymphoma

The Pharmacy Times® Lymphoma Resource Center is a comprehensive resource for clinical news and expert insights on treatments for lymphoma, a cancer that begins in cells of the lymph system. Common treatments for lymphoma may involve chemotherapy, medication, radiation therapy, and stem cell transplant.

FDA Grants Fast Track Designation to CAR T-Cell Therapy That Achieved 100% Complete Response in Lymphoma Patients

December 02, 2022

Article

The allogeneic CAR-T cell therapy is in development for relapsed or refractory large B cell lymphoma and relapsed or refractory B cell non-Hodgkin lymphoma.

Olutasidenib Gains FDA Approval for IDH1-Mutated Relapsed/Refractory Acute Myeloid Leukemia

December 02, 2022

Article

Olutasidenib (Rezlidhia) is indicated for adult patients with relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation detected by an FDA-approved test.

Experimental Type 1 Diabetes Drug Could Slow Growth of Rare Mantle Cell Lymphoma

November 29, 2022

Article

An experimental drug could help scientists understand the development of mantle cell lymphoma and potentially increase overall survival.

Zanubrutinib Shows Superior Progression-Free Survival for Adult Patients with Chronic Lymphocytic Leukemia in Data To Be Presented at ASH 2022

November 29, 2022

Article

Zanubrutinib expressed better cardiac safety measures, higher progression-free survival, and lower discontinuation rates in the ALPINE trial compared with compared ibrutinib.

FDA Accepts BLA for Genmab’s Epcoritamab to Treat Relapsed/Refractory LBCL

November 22, 2022

Article

Agency’s action date is May 21, 2023, for the first subcutaneous bispecific antibody approved for the treatment of large B-cell lymphoma.

Brentuximab Vedotin Approved by FDA for Children With Previously Untreated High-Risk Hodgkin Lymphoma

November 10, 2022

Article

FDA approves brentuximab vedotin for the treatment of patients aged 2 years and older with previously untreated, high-risk classical Hodgkin lymphoma, in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide.

Brentuximab Vedotin Found to Lower Relapse Rate in Pediatric Patients With High-Risk Hodgkin Lymphoma

November 07, 2022

Article

Study shows combining brentuximab vedotin with the standard chemotherapy regimen reduced the risk of relapse in children with high-risk Hodgkin lymphoma by 10%.

Pharmacists in the Oncology Setting: Financial and Clinical Impact is Significant

November 03, 2022

Article

In the inpatient acute care setting, oncology pharmacists maximize return on investments of oncology products, produce optimal outcomes, and ensure that quality of care is consistent and safe.

BLA Submitted for Epcoritamab for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Large B-Cell Lymphoma

November 01, 2022

Article

Epcoritamab is an investigational subcutaneous bispecific antibody being investigated for the treatment of adult patients with relapsed/refractory large B-cell lymphoma.

Interim FDG-PET/CT May Have Positive Prognostic Value for Hodgkin’s Lymphoma

October 26, 2022

Article

Research suggests that positron emission tomography scans are effective at detecting early and late Hodgkin’s lymphoma, and the results could help manage and reduce toxicity from current chemotherapies.